No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VRNA Verona Pharma
- 21.220
- +3.290+18.35%
Close Jul 11 16:00 ET
- 21.280
- +0.060+0.28%
Post 19:59 ET
1.72BMarket Cap-26525P/E (TTM)
21.435High17.961Low3.73MVolume18.030Open17.930Pre Close75.62MTurnover22.41%Turnover RatioLossP/E (Static)81.08MShares23.07052wk High7.65P/B353.51MFloat Cap11.39052wk Low--Dividend TTM16.66MShs Float26.440Historical High--Div YieldTTM19.38%Amplitude2.010Historical Low20.251Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading
European equities traded in the US as American depositary receipts were trending slightly higher late Thursday morning, rising 0.19% to 1,460.27 on the S&P Europe Select ADR Index.From continental
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.6% to 1,436.74 on the S&P Europe Select ADR Index. From continental Europe, the
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending lower late Tuesday morning, declining 0.55% to 1,422.73 on the S&P Europe Select ADR Index. From continental Europe, th
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
H.C. Wainwright analyst Ram Selvaraju maintains $Verona Pharma(VRNA.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 35.8% an
Buy Rating on Verona Pharma: FDA Approval and Strong Market Entry Prospects for Ohtuvayre
Express News | Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $38
Comments
$Verona Pharma(VRNA.US$ and finally it seems all brakes are loose and it is going to the top!
1
$Verona Pharma(VRNA.US$ Price pressure has begun in pre-market, which looks unreal for a company receicing approval for a novel - and potentially groundbreaking - drug.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
4
1
$Verona Pharma(VRNA.US$ shorters will try to push it down. this is a long term hold being a blockbuster drug, with a 2 billion potential further down the road. revenue forecast for this year 40 million. hopefully conference call is giving the price a boost. if a big pharma might do a take over, it goes sky rocketing. whatever it is, don’t sell cheap. Disclaimer: not financial advice.
5
$Verona Pharma(VRNA.US$ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) 2 HOURS AGO, 4:57 PM EDT VIA GLOBENEWSWIRE: Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH,...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg